← back to search

Anastasios Stathis

Institute of Oncology Research · CH
🔎 Find collaborators in Pathology and Forensic Medicine · Genetics →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Protein Degradation and Inhibitors, and Cutaneous lymphoproliferative disorders research.
h-index
40
citations
8,084
works
564
NIH funding
primary concept
Medicine
email

Recent publications

A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA
Blood 2025cited by 13position: middledoi
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study
Blood Advances 2025cited by 2position: middledoi
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study
Haematologica 2023cited by 33position: middledoi
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022
Annals of Oncology 2022cited by 93position: middledoi
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
The Lancet Oncology 2021cited by 412position: middledoi
Genetic and phenotypic attributes of splenic marginal zone lymphoma
Blood 2021cited by 95position: middledoi
Efficacy and Safety Exposure–Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma
The AAPS Journal 2021cited by 11position: middledoi
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734
Blood Advances 2020cited by 71position: middledoi
Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Blood 2020cited by 17position: middledoi
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Clinical Cancer Research 2015cited by 283position: middledoi
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
Clinical Cancer Research 2014cited by 325position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Weiyun Z. Ai · City College of San Francisco4 papers (2020–2023)Juan Pablo Alderuccio · University of Miami4 papers (2020–2023)Melhem Solh · University College London4 papers (2020–2023)Brian Hess · City of Hope4 papers (2020–2023)Kirit M. Ardeshna · University College Hospital3 papers (2020–2023)David Ungar · Adc Therapeutics (Switzerland)3 papers (2020–2021)Brad S. Kahl · New York University3 papers (2020–2023)Pier Luigi Zinzani · Marche Polytechnic University3 papers (2020–2023)Mehdi Hamadani · Medical College of Wisconsin3 papers (2020–2023)John Radford · University of Manchester3 papers (2020–2023)Paolo F. Caimi · Cleveland Clinic3 papers (2020–2023)Carmelo Carlo‐Stella · Humanitas University3 papers (2020–2023) · 2 papers (2015–2020)Francesco Bertoni · Sapienza University of Rome2 papers (2015–2020)Emanuele Zucca · Università della Svizzera italiana2 papers (2015–2020) · 2 papers (2015–2020)Yajuan Qin · PTC Therapeutics (United States)2 papers (2020–2021)Shui He · Guiyang Medical University2 papers (2020–2021)Jay Feingold · Tagworks Pharmaceuticals (Netherlands)2 papers (2020–2021)Luciano Cascione · SIB Swiss Institute of Bioinformatics2 papers (2015–2020)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Pathology and Forensic Medicine · Genetics →